0001493152-22-007326.txt : 20220321 0001493152-22-007326.hdr.sgml : 20220321 20220321080034 ACCESSION NUMBER: 0001493152-22-007326 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220321 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220321 DATE AS OF CHANGE: 20220321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CYTRX CORP CENTRAL INDEX KEY: 0000799698 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 581642750 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-15327 FILM NUMBER: 22754241 BUSINESS ADDRESS: STREET 1: 11726 SAN VICENTE BOULEVARD STREET 2: SUITE 650 CITY: LOS ANGELES STATE: CA ZIP: 90049 BUSINESS PHONE: 310-826-5648 MAIL ADDRESS: STREET 1: 11726 SAN VICENTE BOULEVARD STREET 2: SUITE 650 CITY: LOS ANGELES STATE: CA ZIP: 90049 8-K 1 form8-k.htm
0000799698 false 0000799698 2022-03-21 2022-03-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 21, 2022

 

CYTRX CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware   000-15327   58-1642740
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

11726 San Vicente Boulevard, Suite 650

Los Angeles, California 90049

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (310) 826-5648

 

None

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(g) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered

Common Stock, par value $0.001 per share Series B Junior Participating Preferred Stock Purchase Rights

   CYTR   OTC Markets

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01. Regulation FD Disclosure.

 

On March 21, 2022, CytRx Corporation (the “Company”) issued a press release containing an open letter to its stockholders, attached hereto as Exhibit 99.1, regarding its recent corporate progress. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
Number		   Description
   
99.1   Press Release, dated March 21, 2022 (furnished herewith pursuant to Item 7.01)
104   Cover Page Interactive Data File (formatted as Inline XBRL)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CYTRX CORPORATION
   
Date: March 21, 2022 /s/ John Y. Caloz
  John Y. Caloz
  Chief Financial Officer

 

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress

 

Thanks Stockholders for Supporting Important Proposal at Recent Special Meeting

 

LOS ANGELES—(BUSINESS WIRE)—CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to stockholders.

 

***

 

Dear Stockholders,

 

As we stated at the start of this year, it is the beginning of a new day at CytRx. We know 2022 is a pivotal year for us as we make personnel changes, streamline the business and reenergize innovation of our high-potential Linker Activated Drug Release (“LADR”) platform for the targeted delivery of cancer therapeutics. While there is a lot of work ahead to drive value and sustain your trust, please know that our new leadership team has taken a number of steps in the first quarter:

 

● Integrated Centurion BioPharma Corporation (“Centurion BioPharma”) and its assets into our corporate structure. We believe the LADR platform can help save lives by making cancer drugs work better with an improved safety profile. Our first-generation LADR drug, Aldoxorubicin, has been out-licensed to ImmunityBio, Inc. for royalty and milestone payments of up to $343 million and has produced positive preliminary Phase II data in pancreatic cancer. Our next-generation LADR drugs have undergone extensive testing and development and are not far from being ready for first-in-human studies. These valuable assets belong 100% to CytRx stockholders, so we have folded Centurion BioPharma and the LADR assets into CytRx. This consolidation simplifies our corporate structure and saves money that was being expended on the maintenance of Centurion BioPharma.
   
● Initiated a refresh of our Board of Directors (the “Board”). Steven Kriegsman has retired from the Board and Chairman Dr. Louis Ignarro will retire from the Board prior to the 2022 Annual Meeting. A new independent director, Dr. Jennifer Simpson, joined the Board in 2021, and an additional independent director has been identified and will join the Board as of the 2022 Annual Meeting.
   
● Stepped up communication and engagement with stockholders to explain our long-term vision. Management has more directly engaged with stockholders to make sure we hear and respond to your concerns, and to ensure that we clearly communicate our plan to increase the value of our core assets. This outreach has included direct contact from Company management to stockholders both large and small, and many of the changes made over the past weeks have been a direct result of this communication, so we thank stockholders for taking the time to talk with us and for sharing your ideas.
   
● Recently obtained requisite support from stockholders to increase our number of shares of authorized Common Stock. We greatly appreciate that approximately 73% of stockholders who voted at our recent special meeting supported this important proposal. Authorizing additional Common Shares to convert Armistice Capital’s Preferred Shares to Common Shares saves the Company approximately $1 million in cash that would have been paid to Armistice Capital.

 

Our go-forward priorities include containing costs while exploring partnerships and pathways for advancing our next-generation LADR drugs to human clinical trials. We will remain disciplined and focused as we seek to realize this potential for the benefit of all stockholders.

 

Thank you and we look forward to continuing to engage with you.

 

Stephen Snowdy, Ph.D.

Chief Executive Officer

CytRx Corporation

 

***

 

 
 

 

Forward-Looking Statements

 

This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only CytRx’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of CytRx’s control. Forward-looking statements include those relating to the offering of CytRx’s securities, including as to the consummation of the offering described above, the expected proceeds from the offering, the intended use of proceeds and the timing of the closing of the offering, which may be affected by, among others, delays in satisfying or failure to satisfy closing conditions for the registered direct offering and the concurrent private placement and adverse changes in general economic and market conditions. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements; and other risks and uncertainties described in the most recent annual and quarterly reports filed by the CytRx with the SEC, including disclosures under the heading “Risk Factors”, and current reports filed since the date of the CytRx’s most recent annual report. All forward-looking statements are based upon information available to the CytRx on the date the statements are first published. The CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

About CytRx

 

CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer. CytRx’s most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in two indications, including Niemann-Pick disease Type C (NPC), and Gaucher disease. CytRx Corporation’s website is www.cytrx.com.

 

Contacts

 

Longacre Square Partners
Greg Marose / Bela Kirpalani
cytrx@longacresquare.com

 

 

 

 

 EX-101.SCH 3 cytr-20220321.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cytr-20220321_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 5 cytr-20220321_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
Mar. 21, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 21, 2022
Entity File Number 000-15327
Entity Registrant Name CYTRX CORPORATION
Entity Central Index Key 0000799698
Entity Tax Identification Number 58-1642740
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 11726 San Vicente Boulevard
Entity Address, Address Line Two Suite 650
Entity Address, City or Town Los Angeles
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90049
City Area Code (310)
Local Phone Number 826-5648
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share Series B Junior Participating Preferred Stock Purchase Rights
Trading Symbol CYTR
Entity Emerging Growth Company false
Entity Information, Former Legal or Registered Name None
XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000799698 2022-03-21 2022-03-21 iso4217:USD shares iso4217:USD shares 0000799698 false 8-K 2022-03-21 CYTRX CORPORATION DE 000-15327 58-1642740 11726 San Vicente Boulevard Suite 650 Los Angeles CA 90049 (310) 826-5648 None false false false false Common Stock, par value $0.001 per share Series B Junior Participating Preferred Stock Purchase Rights CYTR false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://cytrx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm cytr-20220321.xsd cytr-20220321_lab.xml cytr-20220321_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "cytr-20220321_lab.xml" ] }, "presentationLink": { "local": [ "cytr-20220321_pre.xml" ] }, "schema": { "local": [ "cytr-20220321.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 60, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "CYTR", "nsuri": "http://cytrx.com/20220321", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-03-21to2022-03-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://cytrx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-03-21to2022-03-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cytrx.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001493152-22-007326-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-007326-xbrl.zip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end